nafamostat has been researched along with Acute Autoimmune Neuropathy in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phongsisay, V | 1 |
| Susuki, K | 1 |
| Matsuno, K | 1 |
| Yamahashi, T | 1 |
| Okamoto, S | 1 |
| Funakoshi, K | 1 |
| Hirata, K | 1 |
| Shinoda, M | 1 |
| Yuki, N | 1 |
1 other study available for nafamostat and Acute Autoimmune Neuropathy
| Article | Year |
|---|---|
Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome.
Topics: Animals; Benzamidines; Complement C3; Complement Inactivating Agents; Disease Models, Animal; Guanid | 2008 |